Helicobacter pylori infection is linked to various gastrointestinal conditions, such as chronic active gastritis, peptic ulcers, and gastric cancer. Traditional treatment options encounter difficulties due to antibiotic resistance and adverse effects. Therefore, the aim of this study was to explore the effectiveness of a new treatment plan that combines vonoprazan (VPZ), amoxicillin, and bismuth for the eradication of H. pylori.

Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in <scp><i>Helicobacter pylori</i></scp>‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial

Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial